Remibrutinib Becomes First On-Label Therapy for Symptomatic Dermographism
Remibrutinib, an oral BTK inhibitor, is the first on-label therapy for symptomatic dermographism. David Cotter, MD, PhD, explains what the label changes for prescribers.
Topic
Btk Inhibitor
Topic
Btk Inhibitor
Remibrutinib Label Expansion and Exosome Advances Headline Dermatology Times Coverage
Dermatology Times flags a remibrutinib label expansion and exosome progress, but the syndicated text names no trials, indications…
Remibrutinib Approval Marks First On-Label Dermographism Drug
Remibrutinib's FDA approval delivers the first on-label systemic therapy for symptomatic dermographism, ending decades of off-lab…
Rhapsido Becomes First FDA-Approved Therapy for Symptomatic Dermographism
Novartis' Rhapsido (remibrutinib) became the first FDA-approved therapy for symptomatic dermographism, extending its reach beyond…
FDA Approves Remibrutinib for Symptomatic Dermographism
The US FDA has approved oral BTK inhibitor remibrutinib for symptomatic dermographism, delivering the first labeled targeted ther…